• Home
  • About
  • UPCOMING WEBINARS & SEMINARS
  • Consultation
  • USP 61/62 FAQ
  • Contact

Barry A. Friedman, PhD LLC

FDA Regulatory Compliance for the Pharmaceutical, Biotechnology and Medical Device Arenas

Upcoming Microbiological Webinars

July 31, 2020 By Barry Friedman Leave a Comment

Enclosed are a series of upcoming microbiological webinars which are being offered between now and the end of September.  While many of us are working from home or in the office on a limited basis, this represents a great opportunity to either gain new skills or refresh those that may require refreshing.  Just click on the title of each webinar to gain additional information or … [Read more...]

U.S. Food and Drug Administration (FDA) Inspection Cites Chinese Firm for API Issues – Includes Import Alert and Warning Letter 

May 28, 2017 By Barry Friedman Leave a Comment

The U.S. Food and Drug Administration (FDA) inspected manufacturing facilities,   Changzhou Jintan Qianyao Pharmaceutical Raw Materials, from February 13-17, 2017.  As a result of significant deviations from current good manufacturing practice (CGMP), the FDA placed the firm on Import Alert 66-40 on May 4, 2017.  Subsequent to … [Read more...]

Frequently Asked Questions (FAQ) About Combination Products

January 13, 2016 By Barry Friedman Leave a Comment

Recently the Office of Combination Products published a list of ”Frequently Asked Questions (FAQ)” that are often asked of the Office.  This list of approximately twenty eight questions include several questions with rather obvious answers as well as questions that include where to obtain additional information regarding annual reports. The list includes the roles of the … [Read more...]

Quality Metrics and Risk Based Inspections

August 1, 2015 By Barry Friedman Leave a Comment

FDA’s Request for Quality Metrics (New Proposed Guidance July 2015) and Its Basis – The FDA’s Safety and Innovation Act (FDASIA) A Live, Interactive Training Webinar; See: http://www.tungstenshield.com/barry-a-friedman-phd/ Date: Tuesday August 18, 2015 Time: 9:30 - 11:30 AM ET (New York Time) Instructor: Barry … [Read more...]

INSPECTION TRACKER: DRUG MANUFACTURING ESTABLISHMENTS (CANADA)

April 7, 2015 By Barry Friedman Leave a Comment

Health Canada Begins Publishing Information Regarding Emerging Issues As part of Health Canada's ongoing commitment to openness and transparency, the Department recently began publishing information regarding emerging issues identified through the drug inspection program. This Inspection Tracker provides a snapshot of the potential health and safety issues Health Canada … [Read more...]

Next Page »
New Reader? Learn More

Connect With Me:

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Webinar Registration & Information

FREQUENTLY ASKED QUESTIONS:

FDA Form 483 Frequently Asked Questions

USP General Chapter

USP General Chapter 62, Part II

TOP OBSERVATIONS:

FDA’s CDER LISTING OF TOP NINETEEN OBSERVATIONS FOR 2014

FDA CDER Most Frequent Form FDA 483 Observations Fiscal Year 2012

CDER MOST FREQUENTLY CITED DRUG OBSERVATIONS – FISCAL YEAR 2010

Top Posts:

Top Posts for 2012

Top Posts for 2013

Top Posts Year To Date

Recent Posts

  • Upcoming Microbiological Webinars
  • Microbiological Webinars
  • Microbiological Webinars 2020 (Upcoming)
  • General Chapter (USP<60>) on B. cepacia Complex to Issue December 1, 2019
  • Les Produits Chimiques B.G.R., Inc. Receives FDA Warning Letter (07/24/2018) for Failure to Perform Laboratory Testing

Categories

follow us in feedly
  • Home
  • About
  • UPCOMING WEBINARS & SEMINARS
  • Consultation
  • USP 61/62 FAQ
  • Contact
  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter

Thank You For Visiting Barry A. Friedman, PhD LLC - 2015

Welcome To My Blog!
Please enter your name and email below to receive my newsletter.
Your information will *never* be shared or sold to a 3rd party.